This inventor holds 11 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Bluebird Bio, Inc., Genetix Pharmaceuticals, Inc., Massachusetts Institute of Technology. Active years: 2002-2017.
Location History:
- Charlestown, FR (2009)
- Charlestown, MA (US) (2002 - 2017)
Company Filing History:
3 out of 34 
3 out of 3 
2 out of 8,573 
Years Active: 2002-2017
Title: **Innovator Philippe Leboulch: Pioneering Advances in Hematology**
Introduction
Philippe Leboulch, an esteemed inventor based in Charlestown, Massachusetts, has made significant contributions to the field of medicine, particularly in hematology. With a remarkable portfolio of 11 patents, his innovations have the potential to revolutionize cancer treatment and gene therapy.
Latest Patents
Among Philippe's notable patents is his groundbreaking work on a combination of an anti-cancer agent—specifically, a tyrosine kinase inhibitor—and a STAT5 antagonist, preferably a thiazolidinedione. This innovative method aims to eliminate hematologic cancer stem cells in vivo and prevent cancer relapse. By employing a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist following an initial treatment with an anti-cancer agent, Philippe's methods target residual cancer stem cells, significantly reducing the chances of relapse.
Additionally, he has developed therapeutic retroviral vectors for gene therapy, which improve the methods and compositions for delivering gene therapy to hematopoietic cells and hematopoietic precursor cells. This advancement is particularly beneficial for treating hematopoietic-related disorders, offering optimized solutions for the expression and treatment of hemoglobinopathic conditions.
Career Highlights
Philippe has garnered substantial experience and recognition in the biotechnology sector through his work at various companies, including Genetix Pharmaceuticals, Inc. His expertise in innovations directly correlates with his commitment to enhancing therapeutic methodologies in cancer treatment and gene therapy.
Collaborations
Philippe's journey has been enriched by collaborations with esteemed colleagues such as Karen Westerman and Naoya Kobayashi. Together, they have contributed to the development of cutting-edge technologies that hold promise for the future of medical treatments, particularly in the field of oncological and hematological therapies.
Conclusion
Philippe Leboulch's prolific contributions to science and medicine exemplify the power of innovation in addressing complex health challenges. His patents not only reflect his dedication to advancing cancer treatment but also position him as a leading figure in gene therapy. As research continues to evolve, Philippe’s work will undoubtedly pave the way for breakthroughs that can improve patient outcomes and redefine therapeutic approaches in hematology.